Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy

Annals of Hematology

Volumn 89, Issue 10, 2010, Pages 985-991

  Song, Moo Kon ^a   Chung, Joo Seop ^a   Sung Yong, Oh ^b   Lee, Gyeong Won ^c   Kim, Seung Geun ^a   Seol, Young Mi ^a   Shin, Ho Jin ^a   Choi, Young Jin ^a   Cho, Goon Jae ^a   Shin, Dong Hoon ^a   Yun, Eun Young ^d  

^a Pusan National University School of Medicine   (South Korea)

^b Dong A University   (South Korea)

^c Gyeongsang National University School of Medicine   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Germinal center; Rituximab

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; LACTATE DEHYDROGENASE; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CONTROLLED STUDY; FEMALE; GENDER; GERMINAL CENTER; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY EXTRANODAL LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GERMINAL CENTER; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 77956686965     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0964-7     Document Type: Article

References (30)

1. F d'Amore BE Christensen H Brincker NT Pedersen K Thorling J Hastrup, et al. 1991 Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group Eur J Cancer 27 1201 1208 10.1016/0277-5379(91)90081-N 1835586
2. C Freeman JW Berg SJ Cutler 1972 Occurrence and prognosis of extranodal lymphomas Cancer 29 252 260 10.1002/1097-0142(197201)29:1<252::AID- CNCR2820290138>3.0.CO;2-# 5007387 1:STN:280:DyaE38%2FotVymug%3D%3D
3. R Newton J Ferlay V Beral SS Devesa 1997 The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites Int J Cancer 72 923 930 10.1002/(SICI)1097-0215(19970917)72:6<923::AID-IJC1>3.0.CO;2-R 9378552 1:STN:280:DyaK1c%2FitFentw%3D%3D (Pubitemid 27433552)
4. R Otter WB Gerrits MM vd Sandt J Hermans R Willemze 1989 Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry Eur J Cancer Clin Oncol 25 1203 1210 10.1016/0277-5379(89)90416-1 2767109 1:STN:280:DyaL1Mzls1OqtA%3D%3D (Pubitemid 19209616)
5. JH van Krieken M Raffeld S Raghoebier ES Jaffe GJ van Ommen PM Kluin 1990 Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas Blood 76 797 800 2200538
6. S Raghoebier MH Kramer JH van Krieken D de Jong J Limpens JC Kluin-Nelemans, et al. 1991 Essential differences in oncogene involvement between primary nodal and extranodal large cell lymphoma Blood 78 2680 2685 1824261 1:STN:280:DyaK38zpvFOmsg%3D%3D
7. HM Clark DB Jones DH Wright 1992 Cytogenetic and molecular studies of t (14;18) and t(14;19) in nodal and extranodal B-cell lymphoma J Pathol 166 129 137 10.1002/path.1711660208 1560313 1:STN:280:DyaK383hvFSnug%3D%3D
8. K Offit F Lo Coco DC Louie NZ Parsa D Leung C Portlock, et al. 1994 Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma N Engl J Med 331 74 80 10.1056/NEJM199407143310202 8208268 1:STN:280:DyaK2c3mvVGhtQ%3D%3D (Pubitemid 24202221)
9. J Houldsworth S Mathew PH Rao K Dyomina DC Louie N Parsa, et al. 1996 REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma Blood 87 25 29 8547649 1:CAS:528:DyaK28XitF2qsg%3D%3D
10. PH Rao J Houldsworth K Dyomina NZ Parsa JC Cigudosa DC Louie, et al. 1998 Chromosomal and gene amplification in diffuse large B-cell lymphoma Blood 92 234 240 9639522 1:CAS:528:DyaK1cXktleqsro%3D
11. Y Natkunam P Farinha ED Hsi CP Hans R Tibshirani LH Sehn, et al. 2008 LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab J Clin Oncol 26 447 454 10.1200/JCO.2007.13.0690 18086797 1:CAS:528:DC%2BD1cXitVGnuro%3D (Pubitemid 351171698)
12. R Malumbres J Chen R Tibshirani NA Johnson LH Sehn Y Natkunam, et al. 2008 Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP Blood 111 5509 5514 10.1182/blood-2008-02- 136374 18445689 1:CAS:528:DC%2BD1cXnsVOkt7o%3D
13. JN Winter EA Weller SJ Horning M Krajewska D Variakojis TM Habermann, et al. 2006 Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Blood 107 4207 4213 10.1182/blood-2005-10-4222 16449523 1:CAS:528:DC%2BD28Xlt1CgsrY%3D (Pubitemid 43801342)
14. N Mounier J Briere C Gisselbrecht JF Emile P Lederlin C Sebban, et al. 2003 Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101 4279 4284 10.1182/blood-2002-11-3442 12576316 1:CAS:528: DC%2BD3sXktFKht7k%3D (Pubitemid 36857789)
15. G Lenz GW Wright NC Emre H Kohlhammer SS Dave RE Davis, et al. 2008 Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proc Natl Acad Sci USA 105 13520 13525 10.1073/pnas.0804295105 18765795
16. H Nyman M Adde ML Karjalainen-Lindsberg M Taskinen M Berglund RM Amini, et al. 2007 Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood 109 4930 4935 10.1182/blood-2006-09-047068 17299093 1:CAS:528:DC%2BD2sXmt1Ogu7Y%3D (Pubitemid 46827791)
17. K Fu DD Weisenburger WW Choi KD Perry LM Smith X Shi, et al. 2008 Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma J Clin Oncol 26 4587 4594 10.1200/JCO.2007.15.9277 18662967 1:CAS:528:DC%2BD1cXht1KqtLfI
18. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 10.1056/NEJMoa011795 11807147 1:CAS:528:DC%2BD38XmslGgsw%3D%3D (Pubitemid 34438862)
19. CP Hans DD Weisenburger TC Greiner RD Gascoyne J Delabie G Ott, et al. 2004 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 275 282 10.1182/blood-2003-05-1545 14504078 1:CAS:528:DC%2BD2cXhsFGhsA%3D%3D (Pubitemid 38029949)
20. TM Habermann EA Weller VA Morrison RD Gascoyne PA Cassileth JB Cohn, et al. 2006 Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diff use large B-cell lymphoma J Clin Oncol 24 3121 3127 10.1200/JCO.2005.05.1003 16754935 1:CAS:528:DC%2BD28XnslKhsL4%3D (Pubitemid 46638950)
21. M Pfreundschuh AD Ho E Cavallin-Stahl M Wolf R Pettengell I Vasova MabThera International Trial (MInT) Group, et al. 2008 Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) Study Lancet Oncol 9 435 444 10.1016/S1470-2045(08)70078-0 18400558
22. AJ Grillo-Lopez 2000 Rituximab: an insider's historical perspective Semin Oncol 27 9 16 11226006 1:CAS:528:DC%2BD3MXitFCis7k%3D
23. DG Maloney B Smith A Rose 2002 Rituximab: mechanism of action and resistance Semin Oncol 29 2 9 10.1053/sonc.2002.30156 11842383 1:CAS:528:DC%2BD38XhvFKksb4%3D
24. MA Shipp KN Ross P Tamayo AP Weng JL Kutok RC Aguiar, et al. 2002 Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning Nat Med 8 68 74 10.1038/nm0102-68 11786909 1:CAS:528:DC%2BD38XjtlygsQ%3D%3D (Pubitemid 34101731)
25. K Kuramoto A Sakai K Shigemasa Y Takimoto H Asaoku T Tsujimoto, et al. 2002 High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma Br J Haematol 116 158 161 10.1046/j.1365-2141.2002.03253.x 11841410 1:CAS:528:DC%2BD38XhvFGkt7k%3D (Pubitemid 34122074)
26. J Rubenstein N Fischbein K Aldape E Burton M Shuman 2002 Hemorrhage and VEGF expression in a case of primary CNS lymphoma J Neurooncol 58 53 56 10.1023/A:1015887312455 12160141 (Pubitemid 34711971)
27. BK Zebrowski S Yano W Liu RM Shaheen DJ Hicklin JB Putnam Jr, et al. 1999 Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions Clin Cancer Res 5 3364 3368 10589746 1:CAS:528:DyaK1MXotV2gs7c%3D
28. M Hockel K Schlenger B Aral M Mitze U Schaffer P Vaupel 1996 Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix Cancer Res 56 4509 4515 8813149 1:STN:280:DyaK28vgvVWjtg%3D%3D
29. G Lenz G Wright SS Dave W Xiao J Powell H Zhao, et al. 2008 Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas N Engl J Med 359 2313 2323 10.1056/NEJMoa0802885 19038878 1:CAS:528:DC%2BD1cXhsVehtbvF
30. D Gratzinger S Zhao RJ Marinelli AV Kapp RJ Tibshirani AS Hammer, et al. 2007 Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes Am J Pathol 170 1362 1369 10.2353/ajpath.2007.060901 17392174 1:CAS:528:DC%2BD2sXkvFymtr8%3D (Pubitemid 47339342)